MUMBAI, March 18 India's BDR Pharmaceuticals
International Pvt Ltd has applied to the Indian patents office,
seeking permission to sell a generic version of Bristol-Myers
Squibb Co's cancer drug, dasatinib, through a so-called
compulsory licence mechanism, a BDR executive said on Monday.
Under a global Trade-Related Aspects of Intellectual
Property Rights (TRIPS) agreement, countries can issue
compulsory licences for certain drugs that are deemed
unaffordable to a large section of their populations.
Early this month, Bayer AG lost an appeal
challenging the first-ever compulsory licence issued by India
which allowed Natco Pharma to sell a version of the
German drugmaker's cancer treatment Nexavar.